Swift Biosciences Launches Accel-Amplicon Plus Cancer Panels for Precision Medicine Initiatives

Food and Healthcare Press Releases Thursday April 19, 2018 14:55
ANN ARBOR, Michigan--19 Apr--PRNewswire/InfoQuest
  • New targeted sequencing workflow combines pre-validated content with easy customization and new analysis tools to accelerate variant discovery and screening

Swift Biosciences today announced the commercial release of its Accel-Amplicon Plus(TM) Cancer NGS Panels , a suite of nine tumor-specific and focused gene panels to facilitate targeted cancer sequencing. The Accel-Amplicon technology enables simultaneous detection of single nucleotide variants, copy number variants and small insertion and deletions to achieve comprehensive and exon-level hotspot coverage of clinically-relevant genes. It also allows researchers to combine pre-validated content and their own targets into a fast, single-tube assay to develop more informative and scalable workflows to better achieve their scientific goals.

Every tumor harbors a unique combination of genomic alterations, which may determine tumor growth rate and response to treatment. Targeted sequencing using focused, multigene panels provides a precise and informative method to quickly identify clinically actionable variants within known or putative cancer genes. However, developing cancer gene panels requires bioinformatics expertise to identify genetic markers and additional resources to design, optimize and validate an assay.

Accel-Amplicon Plus provides a modular, mix-and-match capability that gives translational laboratories greater flexibility to deploy more than one strategy. Laboratories may either begin with a broad gene set to comprehensively profile tumors and then refine the content to the most informative markers, or start with a very focused assay to routinely screen known, clinically actionable variants. Each assay can be designed to accommodate up to 1500 amplicons per panel, are designed and wet-lab validated by Swift's experts, and are fully compatible with degraded FFPE or diluted liquid biopsy samples.

"Accel-Amplicon Plus Cancer Panels could revolutionize cancer and oncology research," said Haley Fiske, Chief Commercial Office at Swift Biosciences. "By integrating pre-validated and customizable content into a single panel, clinical researchers can maximize data generated from every tumor sample and accelerate their efforts to discover and screen cancer variants."

The Accel-Amplicon Plus Cancer Panels consist of nine assays:
Disease Panels
  • Accel-Amplicon Plus(TM) Colorectal Cancer Panel
  • Accel-Amplicon Plus(TM) Lynch Syndrome Panel
  • Accel-Amplicon Plus(TM) Lung Cancer Panel
  • Accel-Amplicon Plus(TM) Myeloid Panel
Gene Panels
  • Accel-Amplicon Plus(TM) 57G Pan-Cancer Profiling Panel
  • Accel-Amplicon Plus(TM) Comprehensive TP53 Gene Panel
  • Accel-Amplicon Plus(TM) BRCA1 and BRCA2 Gene Panel
  • Accel-Amplicon Plus(TM) BRCA 1, BRCA 2 and PALB 2 Gene Panel
  • Accel-Amplicon Plus(TM) EGFR Pathway Panel
Key features and benefits of the Accel-Amplicon Plus Cancer NGS Panels include:
  • Covers thousands of clinically relevant mutations found in the COSMIC and ClinVar databases including those in hotspot regions and at the exon or whole-gene level of key genes
  • Detects rare variants > 1% allele frequency to identify both germline or somatic mutations in the same assay
  • Provides robust performance with as little as 10 nanograms sample input from degraded FFPE samples or limited specimens such as cell-free DNA, fine needle aspirates or other small biopsies
  • Compatible with all Illumina sequencers
With highly informative content, an easy protocol and reliable results, the panels enable several critical oncology applications, including:
  • Low frequency somatic variant discovery or confirmation
  • Tumor profiling in fresh or preserved samples
  • Screening for disease susceptibility, early detection and recurrence
  • Therapeutic efficacy and monitoring

In parallel with the Accel-Amplicon Plus Cancer Panel release, the company launched the Swift Bioinformatics Resources , an offering of open source and commercial solutions to expedite analysis of large NGS data sets. The first two tools support Swift's targeted resequencing workflow, including Primerclip(TM), an open source tool for primer trimming, and FAST Analysis(TM), an intuitive variant detection software from Genialis that seamlessly integrates alignment, allele calling and summary report.

The   Accel-Amplicon Plus Cancer NGS Panels are commercially available now.   Visit www.swiftbiosci.com to learn more.
About Swift Biosciences

Swift Biosciences is the NGS Library Prep company. Based in Ann Arbor, Michigan, the company develops novel library preparation solutions for emerging applications based on next-generation sequencing, including whole genome sequencing, targeted DNA sequencing, and epigenetic analysis.

Swift Biosciences' products are designed to help customers analyze challenging biological samples faster, easier, and with greater sensitivity and accuracy, while being compatible with leading instrumentation. Swift Biosciences is the first company to offer library preparation solutions on all three major sequencing platforms, including Pacific Biosciences(R), Illumina(R) and Ion Torrent(TM).

The company opened its doors in February 2010, and its product development enables new applications in multiple industries, including agrigenomics, pharmaceutical, academic, biotechnology, and oncology research fields.

For more information, visit   SwiftBioSci.com and follow Swift Biosciences on Twitter (@SwiftBioSci).

Latest Press Release

Merck Presents Updated Results for Bifunctional Immunotherapy M7824 at ESMO 2018 Congress

- New data presented at the ESMO 2018 Congress include first disclosure of results for M7824 in advanced squamous cell carcinoma of the head and neck, biliary tract cancer and esophageal cancers - Updated data also being presented include non-small cell...

Menarini Progresses Into the Clinic With MEN1611, a PI3K Inhibitor for the Treatment of HER2 Positive Metastatic Breast Cancer

Menarini Ricerche announced today the initiation of the B-PRECISE-01 clinical trial, a multicenter phase Ib study that will evaluate the safety and efficacy of MEN1611 plus trastuzumab with or without fulvestrant. The study will enroll patients with...

Don#t Miss the Signs of a Breaking Spine, Warns IOF

Osteoporosis, a disease which causes bones to become weak and fragile, is the cause of broken bones in approximately one in three women and one in five men aged over 50 worldwide. (Photo: https://mma.prnewswire.com/media/767079/IOF_Infographic.jpg...

Merck Inaugurates State-of-the-art Pharma Packaging Center in Darmstadt

- Expansion of the pharma manufacturing site at Merck's headquarters supports growth of current and future portfolio of pharma medicines - New building dedicated to the packaging and shipping of Merck's pharma medicines in more than 90 countries - EUR63...

Herbalife Nutrition Survey Reveals Secrets to Healthy Aging, Announces Wellness Tour to Kickstart APAC Consumers# Healthy Aging Journey

As a company whose purpose is to make the world healthier and happier, premier global nutrition company, Herbalife Nutrition, today released findings from its 2018 Asia Pacific Healthy Aging Survey. Conducted in August 2018 with 5,500 respondents aged 40...

Related Topics